Skip to content

Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth

Whole Body Cleansing With 0.25% Chlorhexidine at Birth for Prevention of Sepsis in Infants <1500 g: a Multi-center, Blinded, Randomized Trial

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01723501
Acronym
CAPS
Enrollment
0
Registered
2012-11-08
Start date
2012-11-30
Completion date
Unknown
Last updated
2016-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Mortality Rate, Neonatal Sepsis

Keywords

chlorhexidine, sepsis, neonatal, whole-body skin cleansing

Brief summary

Purpose of this study is determine if skin application of chlorhexidine at birth would reduce infection in infants weighing \<1500 g at birth.

Detailed description

Background Infants weighing \<1500 g at birth infants are more prone to acquire infections, often through their immature skin which serve as a portal of entry for invasive pathogens. Skin application of antiseptics such as chlorhexidine may reduce infections in these infants. However, there is a paucity of data on the safety and efficacy of such intervention in these infants. Hypothesis: Among hospitalized very low birth weight (VLBW; \<1500 g) neonates, single whole body skin cleansing with 0.25% chlorhexidine within 6 hours after birth would reduce the incidence of sepsis in the first seven days of life from 25% to 17.5% (relative reduction of 30%) when compared to skin cleansing with sterile water Objectives: Primary- To evaluate the effect of whole body skin cleansing with 0.25% chlorhexidine (single application, at birth) on the incidence of sepsis (culture positive or culture negative) compared to sterile water cleansing in the first week of life in VLBW infants Secondary- to compare following outcomes in this experiment: 1. Culture-confirmed sepsis within the first week of life 2. Need for repeat hospital admissions within first 28 days of life 3. Mortality within first 28 days of life 4. Cold stress/hypothermia at 0, 5, 15 and 30 minutes of intervention 5. Skin condition at 24 h of life 6. Colonization rates (subset) 7. Serum levels of chlorhexidine (subset) Methods: Eligible infants would be randomized within 6 hours of birth to either whole body skin cleansing with chlorhexidine (specially prepared wipes releasing 0.25% chlorhexidine), or sterile water (placebo). The research staff would collect the baseline data, record the axillary temperature and assess the skin condition using the Newborn Skin Condition Scoring (NSCS)score. The research team would follow the infants for development of sepsis and other outcomes. The infants would be subjected to detailed sepsis work up on clinical suspicion of sepsis, until 28 days of life. Sepsis would be defined based on combination of clinical course, indirect markers, bacterial culture results and antibiotic treatment status.

Interventions

DRUG0.25% chlorhexidine

0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application

DRUGsterile water

Sterile water wipes (placebo)

Sponsors

Maulana Azad Medical College
CollaboratorOTHER
Vardhman Mahavir Medical College And Safdarjung Hospital
CollaboratorOTHER
All India Institute of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
No

Inclusion criteria

* Birth weight less than 1500 g

Exclusion criteria

* Birth weight \<750 g * Major congenital malformations * Total duration of positive pressure ventilation (PPV) \> 3 mins OR chest compressions * Shock- requiring inotropes \>10 mic/kg/min

Design outcomes

Primary

MeasureTime frameDescription
Sepsis within first 7 days of lifeFirst 7 days of lifeSepsis would be defined on the basis of clinical course, lab parameters including culture results and antibiotic treatment given.

Secondary

MeasureTime frameDescription
Readmissions & mortality rates within neonatal period28 daysThe re-admissions & mortality rates within neonatal period in these infants will be prospectively recorded during hospital admission as well as follow up. The follow up includes telephonic contact as well as home visits and verbal autopsy in cases of deaths at home.
Body temperature at 0, 5, 15, 30 minutes after application30 minutesAxillary temperature would be monitored with thermometer at above time points for full three minutes.
Skin condition24 ±6 hoursNewborn Skin Condition Score (NSCS)will be used to assess the skin condition.
Skin colonization rates24 ±6 hoursIn a sub-group of infants, skin swabs will be collected at baseline and 24 ±6 hours and sent to microbiology lab; colonization rates would be determined by semi-quantitative methods.
Chlorhexidine percutaneous absorption48 ±6 hoursSerum chlorhexidine levels will be assayed in a sub-set to assess the extent of percutaneous absorption. 5ml of blood will be stored at -80 deg. C till transport to the lab. Samples will be processed in batches as per standard protocol to determine the levels.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026